Ceftriaxone-Resistant Gonorrhea — China, 2022
MMWR. Morbidity and Mortality Weekly Report·
- DOI
- 10.15585/mmwr.mm7312a2
- PMID
- 38547027
- PMCID
- PMC10986818
- OpenAlex
- W4393260563
- Study type
- Journal article
- Publisher
- Centers for Disease Control MMWR Office
- Article type
- journal-article
- Integrity
- current
Why this research matters now
The substantial increase in ceftriaxone resistance threatens gonorrhea treatment effectiveness in China, where gonorrhea ranked as the fourth most common notifiable infectious disease in 2022 with 96,313 reported cases. Effective diagnosis, treatment, and partner management are essential to prevent transmission of resistant strains.
Structured evidence summary
Research question
The study examined antimicrobial resistance patterns in gonococcal isolates collected through China's national surveillance program in 2022, with particular focus on ceftriaxone resistance trends.
Study design
Surveillance study collecting 2,804 gonococcal isolates from 13 sentinel sites within the China Gonococcal Resistance Surveillance Program, representing approximately 2.9% of all reported gonorrhea cases nationally and 4.1% of cases in participating provinces.
Population and setting
Gonococcal isolates were collected from patients with gonorrhea across 13 provincial-level administrative units in China participating in the China-GRSP network in 2022.
Main findings
Ceftriaxone resistance prevalence reached 8.1% in 2022, approximately three times the 2017 rate of 2.9%, with five provinces exceeding 10% resistance. Resistance prevalences to other antibiotics were: cefixime 16.0%, azithromycin 16.9%, tetracycline 77.1%, penicillin 77.8%, and ciprofloxacin 97.6%, while only one spectinomycin-resistant case was identified.
Public-health relevance
The substantial increase in ceftriaxone resistance threatens gonorrhea treatment effectiveness in China, where gonorrhea ranked as the fourth most common notifiable infectious disease in 2022 with 96,313 reported cases. Effective diagnosis, treatment, and partner management are essential to prevent transmission of resistant strains.
Important limitations
This summary relies on the supplied single-article abstract and metadata. The sentinel surveillance captured only 2.9% of national cases, and geographic representation was limited to 13 of 34 provincial-level administrative units. Full interpretation of resistance mechanisms, risk factors, and clinical outcomes requires access to the complete publication.
GIDS interpretation
This article would be discoverable through classifier links for gonorrhea, antimicrobial resistance, surveillance, and China. The surveillance design and antimicrobial resistance focus align with infectious disease monitoring priorities, though editorial review would assess whether specific resistance thresholds or geographic patterns warrant inclusion in public health alerts.
Related GIDS surveillance
Literature context does not validate, explain, or change a surveillance signal. Exact and contextual relationships are shown separately.
Evidence relationships
This article has 11 auditable classifier relationships to diseases, places, topics, and study design.